What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Immune system
His primary scientific interests are in Immunology, T cell, Cell biology, CD28 and Cytotoxic T cell.
His Immunology research incorporates elements of Receptor and Cancer research.
His T cell research includes themes of Molecular biology, CD3 and CD40.
His biological study spans a wide range of topics, including Immunoglobulin light chain, Antibody and Monoclonal antibody.
In his study, Phosphorylation is strongly linked to T-cell receptor, which falls under the umbrella field of Cell biology.
His Cytotoxic T cell research integrates issues from Mutation, CD8, Viral replication and Virology.
His most cited work include:
- PD-1 antibodies and PD-L1 antibodies and uses thereof (300 citations)
- Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction (260 citations)
- Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. (246 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Immunology, Immune system, T cell, Cell biology and Cancer research.
In his research, Stem cell is intimately related to Transplantation, which falls under the overarching field of Immunology.
His work in Immune system addresses subjects such as Internal medicine, which are connected to disciplines such as Surgery.
The concepts of his T cell study are interwoven with issues in Molecular biology and Cytotoxic T cell, CD40.
His study looks at the relationship between Cell biology and topics such as Receptor, which overlap with Cell.
His Cancer research research is multidisciplinary, incorporating perspectives in Immune checkpoint, Tumor microenvironment, Cancer, Cell culture and Flow cytometry.
He most often published in these fields:
- Immunology (43.97%)
- Immune system (22.09%)
- T cell (21.06%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (18.81%)
- Immune system (22.09%)
- Immunotherapy (13.70%)
In recent papers he was focusing on the following fields of study:
Daniel Olive focuses on Cancer research, Immune system, Immunotherapy, Cancer and Cytotoxic T cell.
His work deals with themes such as Immune checkpoint, Cell, Cancer immunotherapy and Antibody, Monoclonal antibody, which intersect with Cancer research.
Immune checkpoint is a subfield of Immunology that he investigates.
His work carried out in the field of Immune system brings together such families of science as Internal medicine, Melanoma and Oncology.
The Immunotherapy study combines topics in areas such as Cancer cell, Lung cancer and Myeloid leukemia.
Daniel Olive focuses mostly in the field of Cytotoxic T cell, narrowing it down to topics relating to Cytokine and, in certain cases, Pharmacology.
Between 2017 and 2021, his most popular works were:
- Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. (46 citations)
- T lymphocyte subsets in cancer immunity: Friends or foes (39 citations)
- Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. (34 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Immune system
His primary scientific interests are in Cancer research, Immune system, Cancer, Cytotoxic T cell and Immunotherapy.
His studies deal with areas such as Internal medicine and Oncology as well as Immune system.
His Cancer study incorporates themes from Blockade, Antibody and Lung cancer.
His Cytotoxic T cell research is multidisciplinary, incorporating perspectives in Tumor microenvironment, CD8, Germinal center and Interleukin 4.
His research investigates the connection between Immunotherapy and topics such as Myeloid leukemia that intersect with problems in Multiple myeloma, Leukemia, Pomalidomide and Lenalidomide.
His Immune checkpoint study contributes to a more complete understanding of Immunology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
